[{"orgOrder":0,"company":"Kandy Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"NT-814","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Kandy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kandy Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kandy Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"IVIX","sponsor":"Ovoca Bio","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"RUSSIA","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"BP-101","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"IVIX","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"IVIX \/ Ovoca Bio","highestDevelopmentStatusID":"10","companyTruncated":"IVIX \/ Ovoca Bio"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Gedeon Richter","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Gedeon Richter"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Estetrol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Yuyuan BioScience Technology","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Nolasiban","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"ObsEva \/ Yuyuan BioScience Technology","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Yuyuan BioScience Technology"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Farmitalia ","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravaginal","sponsorNew":"Mithra Pharmaceuticals \/ Farmitalia ","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pharmaceuticals \/ Farmitalia "},{"orgOrder":0,"company":"Merck & Co","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Estradiol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Theramex ","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co \/ Theramex "},{"orgOrder":0,"company":"Afaxys Pharma","sponsor":"TherapeuticsMD ","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Segesterone Acetate","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Afaxys Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Afaxys Pharma \/ TherapeuticsMD ","highestDevelopmentStatusID":"12","companyTruncated":"Afaxys Pharma \/ TherapeuticsMD "},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Myovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Sojournix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"SJX-653","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix \/ Not Applicable"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Estetrol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"L-Lactic Acid","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.029999999999999999,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Asarina Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"ValiRx","sponsor":"Undisclosed ","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"VAL301","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"ValiRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"ValiRx \/ Undisclosed ","highestDevelopmentStatusID":"4","companyTruncated":"ValiRx \/ Undisclosed "},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Gynial","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravaginal","sponsorNew":"Mithra Pharmaceuticals \/ Gynial","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pharmaceuticals \/ Gynial"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Plushcare","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Ospemifene","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Duchesnay \/ Plushcare","highestDevelopmentStatusID":"12","companyTruncated":"Duchesnay \/ Plushcare"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Estetrol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Menotropins","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ferring Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Evofem Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Evofem Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"1","companyTruncated":"Evofem Biosciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"Intas Pharmaceuticals","sponsor":"Naari","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Intas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Intas Pharmaceuticals \/ Naari","highestDevelopmentStatusID":"12","companyTruncated":"Intas Pharmaceuticals \/ Naari"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ferrous Gluconate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Etonogestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravaginal","sponsorNew":"Mithra Pharmaceuticals \/ Zentiva","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pharmaceuticals \/ Zentiva"},{"orgOrder":0,"company":"ObsEva","sponsor":"Yuyuan BioScience Technology","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nolasiban","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Dispersible Tablet","sponsorNew":"ObsEva \/ Yuyuan BioScience Technology","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Yuyuan BioScience Technology"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Estetrol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"Nurx","sponsor":"TherapeuticsMD","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Segesterone Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Nurx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravaginal Ring","sponsorNew":"Nurx \/ TherapeuticMD","highestDevelopmentStatusID":"12","companyTruncated":"Nurx \/ TherapeuticMD"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Photodynamic drug","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2020","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.02,"dosageForm":"","sponsorNew":"Palatin Technologies \/ AMAG","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Technologies \/ AMAG"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Demerger","leadProduct":"Etonogestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Merck & Co","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Kandy Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"NT-814","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Kandy Therapeutics","amount2":0.88,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.88,"dosageForm":"Capsule","sponsorNew":"Kandy Therapeutics \/ Bayer Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Kandy Therapeutics \/ Bayer Healthcare"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Estradiol","moa":"Estrogen receptor alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Avomeen","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Ferrous Gluconate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravaginal","sponsorNew":"Dar\u00e9 Bioscience \/ Avomeen","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Bioscience \/ Avomeen"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Monash University","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Vectura Ltd \/ Monash University","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Ltd \/ Monash University"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Sojournix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"SJX-653","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix \/ Not Applicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"TherapeuticsMD","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Estradiol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ TherapeuticsMD","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ TherapeuticsMD"},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"MLE-301","moa":"NK3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Millendo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Millendo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Millendo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sojournix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"SJX-653","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix \/ Not Applicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"LUCA Science","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Mitochondrial therapy","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"LUCA Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"LUCA Science \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"LUCA Science \/ University of Oxford"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"L-Lactic Acid","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.029999999999999999,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Adjuvant Capital","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Adjuvant Capital"},{"orgOrder":0,"company":"Lubrizol Life Science Health","sponsor":"Population Council","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Segesterone Acetate","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Lubrizol Life Science Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Lubrizol Life Science Health \/ Population Council","highestDevelopmentStatusID":"1","companyTruncated":"Lubrizol Life Science Health \/ Population Council"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nolasiban","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Dispersible Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Sterile Inserter","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Menotropins","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Xiromed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Norethisterone Acetate","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Xiromed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Xiromed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xiromed \/ Not Applicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"APL-1702","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ebopiprant","moa":"F2 alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"oral","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Estradiol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"TherapeuticsMD","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"TherapeuticsMD \/ Cantor Fitzgerald","highestDevelopmentStatusID":"12","companyTruncated":"TherapeuticsMD \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Avion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Conjugated Estrogens","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Aspen Pharmacare Holdings \/ Avion Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Pharmacare Holdings \/ Avion Pharmaceuticals"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Population Council","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Segesterone Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravaginal ring","sponsorNew":"Duchesnay \/ Population Council","highestDevelopmentStatusID":"12","companyTruncated":"Duchesnay \/ Population Council"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Amring Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ferring Pharmaceuticals \/ Amring Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Pharmaceuticals \/ Amring Pharmaceuticals"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Norelgestromin","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0.26000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.26000000000000001,"dosageForm":"Transdermal patch","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Gedeon Richter","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Gedeon Richter"},{"orgOrder":0,"company":"Sojournix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"SJX\u2011653","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix \/ Not Applicable"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AMAG Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Iconovo","sponsor":"Monash University","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Iconovo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Iconovo \/ Monash University","highestDevelopmentStatusID":"1","companyTruncated":"Iconovo \/ Monash University"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravaginal gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"MLE-301","moa":"NK3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Millendo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Millendo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Millendo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"Ovoca Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"BP-101","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Ovoca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Ovoca Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovoca Bio \/ Not Applicable"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Cantor","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Estradiol","moa":"Estrogen receptor alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"TherapeuticsMD","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.11,"dosageForm":"Vaginal insert","sponsorNew":"TherapeuticsMD \/ Cantor","highestDevelopmentStatusID":"12","companyTruncated":"TherapeuticsMD \/ Cantor"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"OvaStem","moa":"T Cell","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"NK3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Norelgestromin","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal patch","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Organon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Organon \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Not Applicable"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Drospirenone","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Mithra Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Mayne Pharma \/ Mithra Pharmaceuticals"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Estradiol","moa":"Estrogen receptor alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"transdermal","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.029999999999999999,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Myovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Covis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Covis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Myovant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Myovant","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Myovant"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Drospirenone","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mayne Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Etonogestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Skin Implant","sponsorNew":"Merck & Co \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co \/ Merck"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.050000000000000003,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ H.C. Wainwright","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ H.C. Wainwright"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Pfizer"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Drospirenone","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Mithra Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Mayne Pharma \/ Mithra Pharmaceuticals"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ferring Pharmaceuticals \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Pharmaceuticals \/ Sun Pharma"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tafoxiparin","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Karolinska Development AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ Not Applicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Estradiol Valerate","moa":"Estrogen receptor alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ebopiprant","moa":"F2 alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Follitropin","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ebopiprant","moa":"F2 alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":1,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":1,"dosageForm":"Oral","sponsorNew":"ObsEva \/ Organon","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ Organon"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"NK-1\/NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Sterile Inserter","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Injection","sponsorNew":"Abbott Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Abbott Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Institutional Review Board","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Sublingual Chewing Gum","sponsorNew":"Tauriga Sciences \/ Institutional Review Board","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Institutional Review Board"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"NK-1\/NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Amring Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pierre Fabre \/ Amring Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fabre \/ Amring Pharmaceuticals"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tamoxifen Citrate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"HRA Pharma","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Ulipristal Acetate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"HRA Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HRA Pharma \/ Perrigo","highestDevelopmentStatusID":"12","companyTruncated":"HRA Pharma \/ Perrigo"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Powder for Injection","sponsorNew":"Dexa Medica \/ Debiopharm","highestDevelopmentStatusID":"12","companyTruncated":"Dexa Medica \/ Debiopharm"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Keystone Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Keystone Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Keystone Capital Partners"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Sublingual Chewing Gum","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Theramex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nomegestrol Acetate","moa":"Estrogen receptor alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Theramex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theramex \/ Not Applicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Pfizer"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lactic Acid","moa":"pH level","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tafoxiparin","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Karolinska Development AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ Not Applicable"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0.94999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Chewing Gum","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Iconovo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Oxytocin","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Iconovo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Dry Powder for Inhalation","sponsorNew":"Iconovo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iconovo \/ Not Applicable"},{"orgOrder":0,"company":"AT Research Partners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"Halogenated Fullerene Nanoparticle","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"AT Research Partners","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AT Research Partners \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AT Research Partners \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Emotional Brain BV","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Freya Pharma \/ Emotional Brain BV","highestDevelopmentStatusID":"8","companyTruncated":"Freya Pharma \/ Emotional Brain BV"},{"orgOrder":0,"company":"BCI Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CSF1R kinase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"BCI Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"BCI Pharma \/ Mithra","highestDevelopmentStatusID":"4","companyTruncated":"BCI Pharma \/ Mithra"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Chewing Gum","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0.94999999999999996,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Afaxys Pharma","sponsor":"Agile Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Levonorgestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Afaxys Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Afaxys Pharma \/ Agile Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Afaxys Pharma \/ Agile Therapeutics"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Estetrol","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mithra Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Celmatix","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Celmatix \/ Evotec","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/ Evotec"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Eliapixant","moa":"P2X3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Evotec","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Evotec"},{"orgOrder":0,"company":"Theramex","sponsor":"ObsEva","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theramex \/ ObsEva SA","highestDevelopmentStatusID":"10","companyTruncated":"Theramex \/ ObsEva SA"},{"orgOrder":0,"company":"Theramex","sponsor":"Endoceutics","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Prasterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Pessary","sponsorNew":"Theramex \/ Endoceutics","highestDevelopmentStatusID":"12","companyTruncated":"Theramex \/ Endoceutics"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Desogestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Organon"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"NK3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Film-coated tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Osanetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acer Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jagdale Industries","sponsor":"Bharat Serums & Vaccines ltd","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Isoxsuprine Hydrochloride","moa":"ADRB2","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Jagdale Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jagdale Industries \/ Bharat Serums and Vaccines","highestDevelopmentStatusID":"12","companyTruncated":"Jagdale Industries \/ Bharat Serums and Vaccines"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Norethisterone Acetate","moa":"Sperm penetration","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Slayback Pharma \/ Lupin","highestDevelopmentStatusID":"12","companyTruncated":"Slayback Pharma \/ Lupin"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agile Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Progesterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Pfizer"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Pfizer"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Eptacog Alfa","moa":"Coagulation cascade","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Linzagolix","moa":"GnRH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"ObsEva \/ Theramex","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ Theramex"},{"orgOrder":0,"company":"Fervent Pharmaceuticals","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"FP-101","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Fervent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fervent Pharmaceuticals \/ Iqvia","highestDevelopmentStatusID":"8","companyTruncated":"Fervent Pharmaceuticals \/ Iqvia"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agile Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Pfizer"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Film-coated tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"Theramex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Flaxeed","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theramex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theramex \/ Not Applicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer CentreOne","sponsor":"Effik","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Progesterone","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Pfizer CentreOne","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer CentreOne \/ Effik","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer CentreOne \/ Effik"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Piper Sandler & Co","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Piper Sandler & Co"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Segesterone Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"TherapeuticsMD \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TherapeuticsMD \/ Not Applicable"},{"orgOrder":0,"company":"Celmatix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Celmatix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"LUCA Science","sponsor":"Fast Track Initiative","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"Mitochondrial-based Therapy","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"LUCA Science","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"LUCA Science \/ Fast Track Initiative","highestDevelopmentStatusID":"4","companyTruncated":"LUCA Science \/ Fast Track Initiative"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Pfizer"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Covis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Covis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Theramex","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Theramex","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ Theramex"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Pfizer"},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Piper Sandler & Co.","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.029999999999999999,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Piper Sandler & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Piper Sandler & Co."},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CT-001","moa":"Factor VII","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Coagulant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CT-001","moa":"Factor VIIa","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Coagulant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"SWK Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Leuprolide Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enteris Biopharma Inc \/ SWK Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ SWK Holdings"},{"orgOrder":0,"company":"Organon","sponsor":"Cirqle Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Mushroom-Derived Biopolymer","moa":"Cervical mucus","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Organon","amount2":0.37,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.37,"dosageForm":"Gel","sponsorNew":"Organon \/ Cirqle Biomedical","highestDevelopmentStatusID":"4","companyTruncated":"Organon \/ Cirqle Biomedical"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Norethisterone Acetate","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Rubric Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Segesterone Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"TherapeuticsMD","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.02,"dosageForm":"Implant","sponsorNew":"TherapeuticsMD \/ Rubric Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"TherapeuticsMD \/ Rubric Capital Management"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sciences \/ Pfizer"},{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Provepharm Life Solutions","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Cetrorelix Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Calyptus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Calyptus Pharmaceuticals \/ Provepharm","highestDevelopmentStatusID":"12","companyTruncated":"Calyptus Pharmaceuticals \/ Provepharm"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akorn Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Calyptus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Calyptus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calyptus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"APL-1702","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"PDE5","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Nuvisan GmbH","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Discovery","graph3":"Nuvisan GmbH","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"","sponsorNew":"Nuvisan GmbH \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Nuvisan GmbH \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Rejoy Corporation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"JW-500","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Safety Shot \/ Rejoy Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Safety Shot \/ Rejoy Corporation"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dioscorea Polystachya","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aptorum \/ Not Applicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Aurohealth","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Aurohealth","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Aurohealth \/ Aurobindo Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Aurohealth \/ Aurobindo Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Morningside Pharmaceuticals","sponsor":"Aspire Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Gestodene","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Morningside Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Morningside Pharmaceuticals \/ Aspire Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Morningside Pharmaceuticals \/ Aspire Pharma"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ferrous Gluconate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Bioscience \/ Bayer"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Yuyuan Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nolasiban","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Yuyuan Bioscience","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Yuyuan Bioscience"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Estradiol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Merotocin","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Spray","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ferring Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Leuprolide Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ Not Applicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Pill","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Company plc \/ Not Applicable"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akorn Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"PDE5","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Medicines360","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Medicines360","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Medicines360 \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medicines360 \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Ebopiprant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":0.48999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.48999999999999999,"dosageForm":"","sponsorNew":"ObsEva \/ XOMA","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ XOMA"},{"orgOrder":0,"company":"MedinCell","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Progesterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"MedinCell","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"TherapeuticsMD","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Estradiol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mayne Pharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.23000000000000001,"dosageForm":"Insert","sponsorNew":"Mayne Pharma \/ TherapeuticsMD","highestDevelopmentStatusID":"12","companyTruncated":"Mayne Pharma \/ TherapeuticsMD"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Eunice Kennedy Shriver National Institute Of Child Health","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"Brown Adipose-derived Stem Cells","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Biorestorative Therapies \/ Eunice Kennedy Shriver National Institute Of Child Health","highestDevelopmentStatusID":"1","companyTruncated":"Biorestorative Therapies \/ Eunice Kennedy Shriver National Institute Of Child Health"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SN132D","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Spago Nanomedical \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diclofenac Sodium","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Mayne Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Estradiol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"TherapeuticsMD","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.23000000000000001,"dosageForm":"Insert","sponsorNew":"TherapeuticsMD \/ Mayne Pharma","highestDevelopmentStatusID":"12","companyTruncated":"TherapeuticsMD \/ Mayne Pharma"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Estradiol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Estradiol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Patch","sponsorNew":"Agile Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agile Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Osanetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Acer Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AMY109","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Diclofenac Sodium","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NativusWell","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aptorum \/ Not Applicable"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CT-001","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Coagulant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Follitropin Delta","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ferring Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Norethisterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Osanetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acer Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Alter Pharma group","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Magnesium Sulfate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Athenex \/ Alter Pharma Group","highestDevelopmentStatusID":"12","companyTruncated":"Athenex \/ Alter Pharma Group"},{"orgOrder":0,"company":"NEXT Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Vasalgel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"NEXT Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NEXT Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NEXT Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Company plc \/ Not Applicable"},{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CBP-4888","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Comanche Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Comanche Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Comanche Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AMAG Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Celmatix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Celmatix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Pill","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Company plc \/ Not Applicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Drospirenone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Pill","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Epoxyestrenolone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Endoceutics","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Prasterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Endoceutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Endoceutics \/ Cosette Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Endoceutics \/ Cosette Pharma"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"vitaCare Prescription Services","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Agile Therapeutics \/ vitaCare Prescription Services","highestDevelopmentStatusID":"12","companyTruncated":"Agile Therapeutics \/ vitaCare Prescription Services"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"BCI Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Mithra Pharmaceuticals \/ BCI Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Mithra Pharmaceuticals \/ BCI Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Aurisco Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dydrogesterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Aurisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurisco Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurisco Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"Patch","sponsorNew":"Agile Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Agile Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2021","type":"Demerger","leadProduct":"Etonogestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Merck & Co \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co \/ Organon"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Ganirelix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AB Brunna \/ Not Applicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Yuyuan","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Termination","leadProduct":"Nolasiban","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Yuyuan","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Yuyuan"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies, LLC","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies, LLC"},{"orgOrder":0,"company":"Endo International","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Oxytocin","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Endo International \/ Premier","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Premier"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Company plc \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"National Institute of Child Health and Human Development","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Dar\u00e9 Bioscience \/ National Institute of Child Health and Human Development","highestDevelopmentStatusID":"4","companyTruncated":"Dar\u00e9 Bioscience \/ National Institute of Child Health and Human Development"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"SEARCHLIGHT PHARMA INC","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Searchlight Pharma Inc","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Searchlight Pharma Inc"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.050000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Fuji Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pharmaceuticals \/ Fuji Pharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Medroxyprogesterone Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Celmatix","sponsor":"Ache Laboratorios Farmaceuticos SA","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Celmatix \/ Ache Laboratorios Farmaceuticos SA","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/ Ache Laboratorios Farmaceuticos SA"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Inositol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"BIOSYENT PHARMA INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BIOSYENT PHARMA INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BIOSYENT PHARMA INC \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Palatin Technologies \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Technologies \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"siRNA-2283","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Comanche Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Comanche Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Comanche Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Estetrol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Mithra Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Mithra Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Mithra Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Estradiol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Estradiol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Pherin Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"PH80","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Pherin Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Pherin Pharmaceuticals"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Sumitomo","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Relugolix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Sumitomo","highestDevelopmentStatusID":"12","companyTruncated":"Gedeon Richter \/ Sumitomo"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Photocure","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"APL-1702","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Asieris Pharmaceuticals \/ Photocure","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Photocure"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"NICHD","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.050000000000000003,"dosageForm":"Implant","sponsorNew":"Dar\u00e9 Bioscience \/ NICHD","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ NICHD"},{"orgOrder":0,"company":"Viatris","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Dydrogesterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Viatris","amount2":3.3700000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":3.3700000000000001,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Theramex","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Theramex"},{"orgOrder":0,"company":"Viatris","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Dydrogesterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Viatris \/ Theramex","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Theramex"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Relugolix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sumitomo \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo \/ Pfizer Inc"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.050000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Fuji Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pharmaceuticals \/ Fuji Pharma"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"SEARCHLIGHT PHARMA INC","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Searchlight Pharma Inc","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Searchlight Pharma Inc"},{"orgOrder":0,"company":"Freya Biosciences","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2023","type":"Series A Financing","leadProduct":"FB101","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Freya Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Freya Biosciences \/ Sofinnova Partners","highestDevelopmentStatusID":"6","companyTruncated":"Freya Biosciences \/ Sofinnova Partners"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Aditxt","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"L-Lactic Acid","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Aditxt","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Biosciences \/ Aditxt"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Bio-identical Progesterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Dar\u00e9 Bioscience \/ National Institutes of Health"},{"orgOrder":0,"company":"Tiumbio","sponsor":"SK Chemicals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Merigolix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tiumbio \/ SK Chemicals","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ SK Chemicals"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2024","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Technologies \/ Cosette Pharma"},{"orgOrder":0,"company":"Bonafide Health","sponsor":"Pharmavite","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Bonafide Pollen","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bonafide Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bonafide Health \/ Pharmavite","highestDevelopmentStatusID":"12","companyTruncated":"Bonafide Health \/ Pharmavite"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Technologies \/ Cosette Pharma"},{"orgOrder":0,"company":"MenoLabs","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Bifidobacterium Animalis","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"MenoLabs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MenoLabs \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"MenoLabs \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Heranova Lifesciences","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Heranova Lifesciences","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"","sponsorNew":"Heranova Lifesciences \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Heranova Lifesciences \/ Pivotal bioVenture Partners"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Large molecule","year":"2024","type":"Series B Financing","leadProduct":"CBP-4888","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Comanche Biopharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Comanche Biopharma \/ Google Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Comanche Biopharma \/ Google Ventures"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2023","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Technologies \/ Cosette Pharma"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Relugolix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gedeon Richter \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Estetrol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Diclofenac","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ganirelix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Estetrol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Gynica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabinoid-based Drug","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Gynica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Gynica \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gynica \/ Not Applicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Estetrol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"DARA BIOSCIENCES","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tamoxifen Citrate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"DARA BIOSCIENCES","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"DARA BIOSCIENCES \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"DARA BIOSCIENCES \/ Not Applicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Estetrol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Sodium Hyaluronate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"BIOSYENT PHARMA INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Suppository","sponsorNew":"BIOSYENT PHARMA INC \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"BIOSYENT PHARMA INC \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.050000000000000003,"dosageForm":"Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Ferrous Gluconate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.02,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ XOMA","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Bioscience \/ XOMA"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Merigolix","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tiumbio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ Not Applicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Apotex Fermentation Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fermentation Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"OLIC","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Drospirenone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Lupin Ltd \/ OLIC","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ OLIC"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Insud Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Levonorgestrel","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Agile Therapeutics \/ Insud Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Agile Therapeutics \/ Insud Pharma"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NOE-115","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Noema Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Noema Pharma \/ Not Applicable"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Douglas CDMO develops, manufactures, and packs various dosage forms, and provides regulatory support for international distribution.
